About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« South African Minister of Science and Technology and Other IP Leaders to Speak at Conference on "Accelerating IP and Innovation in South Africa" | Main | Is the End of Fee Diversion Dead in the Leahy-Smith America Invents Act? »

June 19, 2011

Court Report

By Sherri Oslick --

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Somaxon Pharmaceuticals Inc. et al. v. Zydus Pharmaceuticals (USA) Inc. et al.
1:11-cv-00537; filed June 16, 2011 in the District Court of Delaware

• Plaintiffs:  Somaxon Pharmaceuticals Inc.; Procom One Inc.
• Defendants:  Zydus Pharmaceuticals (USA) Inc.; Cadila Healthcare Ltd.

Infringement of U.S. Patent Nos. 6,211,229 ("Treatment of Transient and Short Term Insomnia," issued April 3, 2001) and 7,915,307 ("Methods of Improving the Pharmacokinetics of Doxepin," issued March 29, 2011) following Zydus' filing of an ANDA to manufacture a generic version of Somaxon's Silenor® (doxepin, used to treat insomnia).  View the complaint here.


Alcon Research, Ltd. et al. v. Watson Laboratories, Inc. et al.
1:11-cv-00786; filed June 9, 2011 in the Southern District of Indiana

• Plaintiffs: vAlcon Research, Ltd.; Alcon Pharmaceuticals, Ltd.; Kyowa Hakko Kirin Co., Ltd.
• Defendants:  Watson Laboratories, Inc.; Watson Pharmaceuticals, Inc.; Watson Pharma, Inc.

Infringement of U.S. Patent Nos. 5,641,805 ("Topical Ophthalmic Formulations for Treating Allergic Eye Diseases," issued June 24, 1997), 6,995,186 ("Olopatadine Formulations for Topical Administration," issued on February 7, 2006), and 7,402,609 (same title, issued July 22, 2008) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Alcon's Pataday® (olopatadine hydrochloride ophthalmic solution, used to treat ocular itching associated with allergic conjunctivitis).  View the complaint here.

Posted at 11:18 PM in Court Report |

Comments

The comments to this entry are closed.

September 2024

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

Categories

Archives

More...